Based on a similar concept, novel NK cell engagers (NKCE), synthetic molecules composed of the fragments of monoclonal antibodies that simultaneously engage NK activating receptors and tumor antigens, have been designed (112, 113). This evidence concerns the gene SLAMF6 and neoplasm.